Related Experiment Video
Updated: Jul 9, 2026
11:16
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Gene therapy for chronic granulomatous disease
Martin F Ryser1, Joachim Roesler, Marcus Gentsch
1University Clinic Carl Gustav Carus Dresden, Department of Pediatrics, Building 21, Fetscher Street 74 , 01307 Dresden, Germany.
Expert Opinion on Biological Therapy
|November 24, 2007
Summary
Gene therapy offers a potential cure for chronic granulomatous disease (CGD) by correcting the genetic defect. Recent advancements show clinical benefit, but safety concerns like insertional mutagenesis require further research for improved vector systems.
Area of Science:
- Immunology
- Hematology
- Genetic Medicine
Background:
- Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired reactive oxygen metabolite production, leading to severe infections and inflammation.
- Hematopoietic stem cell transplantation is a curative option for CGD, but its application is limited by donor availability and treatment failure with conventional therapies.
Purpose of the Study:
- To review the progress and challenges of gene therapy for chronic granulomatous disease.
- To highlight the potential of improved gene therapy strategies for treating CGD.
Main Methods:
- Review of clinical trials and research investigating gene therapy for CGD since 1997.
- Analysis of vector systems, engraftment efficiency, and safety profiles, including insertional mutagenesis.
Main Results:
- Early gene therapy trials showed limited cell engraftment, while recent studies with busulfan conditioning improved clinical outcomes.
- Concerns regarding insertional mutagenesis and dominant clone emergence have been identified in CGD and related immunodeficiency trials.
- Development of modified vector systems with reduced genotoxicity in preclinical studies.
Conclusions:
- Gene therapy holds significant promise for curing CGD, with recent trials demonstrating clinical efficacy.
- Addressing safety concerns, particularly insertional mutagenesis, is crucial for the advancement of CGD gene therapy.
- Future gene therapy protocols aim for efficient, durable gene transfer with minimized genotoxic risks, positioning it as a key therapeutic option.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
02:32Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...